Merus N.V. (MRUS)
| Market Cap | 1.14B |
| Revenue (ttm) | 43.41M |
| Net Income (ttm) | -80.36M |
| Shares Out | 42.67M |
| EPS (ttm) | -2.25 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 136,751 |
| Open | 28.18 |
| Previous Close | 28.46 |
| Day's Range | 26.74 - 28.50 |
| 52-Week Range | 16.14 - 33.09 |
| Beta | 0.97 |
| Analysts | Strong Buy |
| Price Target | 42.67 (+59.3%) |
| Earnings Date | Nov 4, 2021 |
About MRUS
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trial for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 for the pancreatic and lung cancer, and other solid tumors. The company is also developing MCLA-117 that is in phase I clinical trial for the treatment of patients with acute myeloid leukemia; MCLA-1...
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for Merus stock is "Strong Buy." The 12-month stock price forecast is 42.67, which is an increase of 59.26% from the latest price.
News
Merus Presents Updated Analysis of Zenocutuzumab, Trastuzumab, and Vinorelbine in Patients with HER2+ Metastatic Brea...
- The primary endpoint of Clinical Benefit Rate at 24 weeks with the triplet combination was met
Merus Presents Clinical Data on MCLA-145 at the ESMO Immuno-Oncology Congress 2021
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovati...
Merus N.V. Announces Proposed Public Offering of Common Shares
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovati...
Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates
Merus N.V. (MRUS) delivered earnings and revenue surprises of 40.91% and 29.84%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Merus Announces Regulatory Update on Zenocutuzumab, Financial Results for the Third Quarter and Provides Business Update
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we”, or “our”), a clinical-stage oncology company developing innovat...
Will Merus N.V. (MRUS) Report Negative Q3 Earnings?
Merus N.V. (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Merus N.V. (MRUS): Can Its 37.5% Jump Turn into More Strength?
Merus N.V. (MRUS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in...
Here's Why Merus Stock Is Flying Higher Today
This biotech's second experimental cancer drug to begin clinical trials produced some encouraging results.
Merus Presents Early Clinical Data on MCLA-158 and Preclinical Data on Zenocutuzumab at the AACR-NCI-EORTC Virtual In...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovati...
Merus Announces Poster Presentations on Zenocutuzumab and MCLA-158 at the AACR-NCI-EORTC Virtual International Confer...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovat...
Merus N.V. (MRUS) Reports Q2 Loss, Tops Revenue Estimates
Merus N.V. (MRUS) delivered earnings and revenue surprises of -18.33% and 58.06%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Merus Announces Financial Results for the Second Quarter and Provides Business Update
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we”, or “our”), a clinical-stage oncology company developing innovati...
Earnings Preview: Merus N.V. (MRUS) Q2 Earnings Expected to Decline
Merus N.V. (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merus to Participate in William Blair's Biotech Focus Conference 2021
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies ...
Merus Presents Clinical Data on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Clinical Onco...
- 61 patients with NRG1+ cancer have been enrolled, including 45 patients evaluable for response as of the April 13, 2021 data cutoff date- Encouraging early clinical activity observed, with confirmed...
Merus to Participate in a Fireside Chat at the Jefferies Virtual Healthcare Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (...
Merus Announces Publication of Abstract on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Cl...
- 51 patients with NRG1+ cancer have been treated, including 33 patients evaluable for response, as of the January 12, 2021, data cutoff date- Encouraging early clinical activity observed, with conf...
Merus N.V. (MRUS) Moves 13% Higher: Will This Strength Last?
Merus N.V. (MRUS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Merus N.V. (MRUS) Reports Q1 Loss, Lags Revenue Estimates
Merus N.V. (MRUS) delivered earnings and revenue surprises of -27.27% and -63.08%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Merus Announces Financial Results for the First Quarter and Provides Business Update
Clinical data update on zenocutuzumab selected for oral presentation at ASCO MCLA-145 clinical update planned for 2H21 MCLA-129 first patient dosed in phase 1/2 trial Cecile Geuijen, Ph.D., promoted ...
Merus Announces First Patient Treated in Phase 1/2 Clinical Trial of MCLA-129 in Advanced Lung Cancer and Other Solid...
Merus' Fourth Sponsored Bispecific Antibody Currently in Clinical Trials Merus' Fourth Sponsored Bispecific Antibody Currently in Clinical Trials
Zenocutuzumab Clinical Data Selected for Oral Presentation at the 2021 American Society of Clinical Oncology Annual M...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovat...
Merus N.V. (MRUS) Reports Q4 Loss, Tops Revenue Estimates
Merus N.V. (MRUS) delivered earnings and revenue surprises of -26.23% and 11.19%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Merus Announces Financial Results for the Fourth Quarter and Full Year 2020 and Provides Business Update
Clinical data and program update planned for lead program zenocutuzumab (“Zeno”) in 2Q 2021
Merus Announces Poster Presentations for Zenocutuzumab and MCLA-129 at the American Association for Cancer Research 2...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovat...